A meta-analysis of osteoporosis drugs showed that change in DXA BMD was a surrogate for fracture risk. If accepted by the FDA, it would ‘really open up the field to a lot of new treatments.’
Medscape Medical News …read more
A meta-analysis of osteoporosis drugs showed that change in DXA BMD was a surrogate for fracture risk. If accepted by the FDA, it would ‘really open up the field to a lot of new treatments.’
Medscape Medical News …read more
Comments are closed.
Nice posts! 🙂
___
Sanny